Published in J Immunol on May 09, 2012
Implications of DPP4 modification of proteins that regulate stem/progenitor and more mature cell types. Blood (2013) 1.18
Acanthamoeba protease activity promotes allergic airway inflammation via protease-activated receptor 2. PLoS One (2014) 0.90
Angiotensin-(1-7) attenuates airway remodelling and hyperresponsiveness in a model of chronic allergic lung inflammation. Br J Pharmacol (2015) 0.80
Gene expression profiling following NRF2 and KEAP1 siRNA knockdown in human lung fibroblasts identifies CCL11/Eotaxin-1 as a novel NRF2 regulated gene. Respir Res (2012) 0.79
Commentary: IL-4 and IL-13 receptors and signaling. Cytokine (2015) 0.77
Leukotriene enhanced allergic lung inflammation through induction of chemokine production. Clin Exp Med (2014) 0.76
IL-13 receptor α2 is a negative prognostic factor in human lung cancer and stimulates lung cancer growth in mice. Oncotarget (2015) 0.76
PLAG (1-Palmitoyl-2-Linoleoyl-3-Acetyl-rac-Glycerol) Modulates Eosinophil Chemotaxis by Regulating CCL26 Expression from Epithelial Cells. PLoS One (2016) 0.75
Regulation of CBL and ESR1 expression by microRNA-22‑3p, 513a-5p and 625-5p may impact the pathogenesis of dust mite-induced pediatric asthma. Int J Mol Med (2016) 0.75
An Overlook to the Characteristics and Roles Played by Eotaxin Network in the Pathophysiology of Food Allergies: Allergic Asthma and Atopic Dermatitis. Inflammation (2016) 0.75
Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med (1991) 16.81
Role of transforming growth factor beta in human disease. N Engl J Med (2000) 10.17
Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest (1999) 8.38
Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med (2009) 8.36
Essential role of Stat6 in IL-4 signalling. Nature (1996) 6.56
Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med (2002) 4.67
Identification of unknown target genes of human transcription factors using chromatin immunoprecipitation. Methods (2002) 3.37
Airway remodeling in asthma. J Clin Invest (1999) 3.19
Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med (2011) 2.80
Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response. J Exp Med (2003) 2.71
Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. J Immunol (1988) 2.70
TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J (2007) 2.57
Activation of eotaxin gene transcription by NF-kappa B and STAT6 in human airway epithelial cells. J Immunol (1999) 1.83
Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways. J Biol Chem (2007) 1.73
Interleukin-13 in asthma. Curr Opin Pulm Med (2003) 1.66
Cytokines and growth factors in airway remodeling in asthma. Curr Opin Immunol (2007) 1.66
Kinetics of eotaxin generation and its relationship to eosinophil accumulation in allergic airways disease: analysis in a guinea pig model in vivo. J Exp Med (1997) 1.61
Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells. J Immunol (1999) 1.59
Regulation of eotaxin gene expression by TNF-alpha and IL-4 through mRNA stabilization: involvement of the RNA-binding protein HuR. J Immunol (2003) 1.57
Interleukin-13 and tumour necrosis factor-alpha synergistically induce eotaxin production in human nasal fibroblasts. Clin Exp Allergy (2000) 1.49
Persistent effects induced by IL-13 in the lung. Am J Respir Cell Mol Biol (2006) 1.47
CD4(+) T helper cells engineered to produce latent TGF-beta1 reverse allergen-induced airway hyperreactivity and inflammation. J Clin Invest (2000) 1.43
Interleukin-13 upregulates eotaxin expression in airway epithelial cells by a STAT6-dependent mechanism. Am J Respir Cell Mol Biol (2001) 1.42
Interleukin-13 mediates airways hyperreactivity through the IL-4 receptor-alpha chain and STAT-6 independently of IL-5 and eotaxin. Am J Respir Cell Mol Biol (2001) 1.41
Selective induction of eotaxin release by interleukin-13 or interleukin-4 in human airway smooth muscle cells is synergistic with interleukin-1beta and is mediated by the interleukin-4 receptor alpha-chain. Am J Respir Crit Care Med (2002) 1.40
IL-13 and IL-4 cause eotaxin release in human airway smooth muscle cells: a role for ERK. Am J Physiol Lung Cell Mol Physiol (2002) 1.34
Intestinal macrophage/epithelial cell-derived CCL11/eotaxin-1 mediates eosinophil recruitment and function in pediatric ulcerative colitis. J Immunol (2008) 1.33
IL-13 induces connective tissue growth factor in rat hepatic stellate cells via TGF-β-independent Smad signaling. J Immunol (2011) 1.32
Regulatory T cells in many flavors control asthma. Mucosal Immunol (2010) 1.28
Analysis of the life cycle of stat6. Continuous cycling of STAT6 is required for IL-4 signaling. J Biol Chem (2002) 1.28
Cytokine regulation of IL-13Ralpha2 and IL-13Ralpha1 in vivo and in vitro. J Allergy Clin Immunol (2003) 1.27
Increased TGF-beta2 in severe asthma with eosinophilia. J Allergy Clin Immunol (2005) 1.27
TGF-beta and IL-13 synergistically increase eotaxin-1 production in human airway fibroblasts. J Immunol (2002) 1.22
Eotaxin expression and eosinophilic inflammation in asthma. Biochem Biophys Res Commun (1997) 1.14
Reduced expression of transforming growth factor beta 1 exacerbates pathology in an experimental asthma model. Eur J Immunol (2005) 1.11
Regional fibroblast heterogeneity in the lung: implications for remodeling. Am J Respir Crit Care Med (2006) 1.10
STAT6 mediates eotaxin-1 expression in IL-4 or TNF-alpha-induced fibroblasts. J Immunol (2001) 1.10
Induction of the IL-13 receptor alpha2-chain by IL-4 and IL-13 in human keratinocytes: involvement of STAT6, ERK and p38 MAPK pathways. Oncogene (2001) 1.07
Induction of eotaxin expression and release from human airway smooth muscle cells by IL-1beta and TNFalpha: effects of IL-10 and corticosteroids. Br J Pharmacol (1999) 1.05
The CC chemokine eotaxin/CCL11 has a selective profibrogenic effect on human lung fibroblasts. J Allergy Clin Immunol (2005) 1.03
Genomic organization, sequence, and transcriptional regulation of the human eotaxin gene. Biochem Biophys Res Commun (1997) 1.01
Eotaxin protein and gene expression in guinea-pig lungs: constitutive expression and upregulation after allergen challenge. Eur Respir J (1997) 1.01
Interleukin-1-induced nuclear factor-kappaB-IkappaBalpha autoregulatory feedback loop in hepatocytes. A role for protein kinase calpha in post-transcriptional regulation of ikappabalpha resynthesis. J Biol Chem (1999) 1.00
Dysregulation of the IL-13 receptor system: a novel pathomechanism in pulmonary arterial hypertension. Am J Respir Crit Care Med (2010) 1.00
Interleukin-13 augments transforming growth factor-beta1-induced tissue inhibitor of metalloproteinase-1 expression in primary human airway fibroblasts. Am J Physiol Cell Physiol (2004) 0.93
Synergistic induction of eotaxin expression in human keratocytes by TNF-alpha and IL-4 or IL-13. Invest Ophthalmol Vis Sci (2000) 0.93
TGF-beta differentially regulates TH2 cytokine-induced eotaxin and eotaxin-3 release by human airway smooth muscle cells. J Allergy Clin Immunol (2004) 0.91
TNF-alpha and IL-4 regulate expression of IL-13 receptor alpha2 on human fibroblasts. Biochem Biophys Res Commun (2003) 0.89
Interleukin 6 is autoregulated by transcriptional mechanisms in cultures of rat osteoblastic cells. J Clin Invest (1997) 0.87
IFN-gamma, IL-4 and IL-13 modulate responsiveness of human airway smooth muscle cells to IL-13. Respir Res (2008) 0.87
The fast chromatin immunoprecipitation method. Methods Mol Biol (2009) 0.86
Transforming growth factor-β stimulates the expression of eotaxin/CC chemokine ligand 11 and its promoter activity through binding site for nuclear factor-κβ in airway smooth muscle cells. Clin Exp Allergy (2010) 0.82
An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med (2009) 9.38
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J (2013) 8.39
Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med (2009) 7.17
Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol (2007) 6.33
Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med (2014) 4.95
Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. Nat Genet (2011) 3.68
Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol (2011) 3.35
A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med (2010) 3.11
Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol (1985) (2007) 2.83
Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol (2004) 2.80
Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. J Allergy Clin Immunol (2010) 2.27
Epithelial eotaxin-2 and eotaxin-3 expression: relation to asthma severity, luminal eosinophilia and age at onset. Thorax (2012) 2.14
Severe asthma in adults: what are the important questions? J Allergy Clin Immunol (2007) 1.85
An association between L-arginine/asymmetric dimethyl arginine balance, obesity, and the age of asthma onset phenotype. Am J Respir Crit Care Med (2012) 1.85
Function and regulation of SPLUNC1 protein in Mycoplasma infection and allergic inflammation. J Immunol (2007) 1.85
Pulmonary function abnormalities in HIV-infected patients during the current antiretroviral therapy era. Am J Respir Crit Care Med (2010) 1.81
Asthma in older adults: observations from the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study. Ann Allergy Asthma Immunol (2006) 1.77
Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. Am J Respir Crit Care Med (2011) 1.76
Correlation of systemic superoxide dismutase deficiency to airflow obstruction in asthma. Am J Respir Crit Care Med (2005) 1.72
Gene expression in relation to exhaled nitric oxide identifies novel asthma phenotypes with unique biomolecular pathways. Am J Respir Crit Care Med (2014) 1.69
Obesity and asthma: an association modified by age of asthma onset. J Allergy Clin Immunol (2011) 1.64
Mast cell phenotype, location, and activation in severe asthma. Data from the Severe Asthma Research Program. Am J Respir Crit Care Med (2010) 1.62
Importance of hedgehog interacting protein and other lung function genes in asthma. J Allergy Clin Immunol (2011) 1.58
Transforming growth factor-beta2 induces bronchial epithelial mucin expression in asthma. Am J Pathol (2004) 1.58
IL4R alpha mutations are associated with asthma exacerbations and mast cell/IgE expression. Am J Respir Crit Care Med (2006) 1.57
Interleukin-15 inhibits spontaneous apoptosis in human eosinophils via autocrine production of granulocyte macrophage-colony stimulating factor and nuclear factor-kappaB activation. Am J Respir Cell Mol Biol (2002) 1.57
Eosinophils in asthma--closing the loop or opening the door? N Engl J Med (2009) 1.49
Recent asthma exacerbations: a key predictor of future exacerbations. Respir Med (2006) 1.49
Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. Chest (2007) 1.47
Predicting future risk of asthma exacerbations using individual conditional probabilities. J Allergy Clin Immunol (2011) 1.46
Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. Am J Respir Crit Care Med (2008) 1.45
Severity assessment in asthma: An evolving concept. J Allergy Clin Immunol (2005) 1.42
Associations between fluctuations in lung function and asthma control in two populations with differing asthma severity. Thorax (2011) 1.39
Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol (2009) 1.38
Early infection with respiratory syncytial virus impairs regulatory T cell function and increases susceptibility to allergic asthma. Nat Med (2012) 1.33
Defective apoptotic cell phagocytosis attenuates prostaglandin E2 and 15-hydroxyeicosatetraenoic acid in severe asthma alveolar macrophages. Am J Respir Crit Care Med (2005) 1.27
Increased TGF-beta2 in severe asthma with eosinophilia. J Allergy Clin Immunol (2005) 1.27
Predicting intermediate phenotypes in asthma using bronchoalveolar lavage-derived cytokines. Clin Transl Sci (2010) 1.25
15-Lipoxygenase 1 interacts with phosphatidylethanolamine-binding protein to regulate MAPK signaling in human airway epithelial cells. Proc Natl Acad Sci U S A (2011) 1.23
TGF-beta and IL-13 synergistically increase eotaxin-1 production in human airway fibroblasts. J Immunol (2002) 1.22
Registration-based assessment of regional lung function via volumetric CT images of normal subjects vs. severe asthmatics. J Appl Physiol (1985) (2013) 1.22
Selective downregulation of prostaglandin E2-related pathways by the Th2 cytokine IL-13. J Allergy Clin Immunol (2006) 1.21
Subepithelial basement membrane immunoreactivity for matrix metalloproteinase 9: association with asthma severity, neutrophilic inflammation, and wound repair. J Allergy Clin Immunol (2003) 1.20
Neutrophil-derived matrix metalloproteinase-9 is increased in severe asthma and poorly inhibited by glucocorticoids. J Allergy Clin Immunol (2003) 1.19
Exhaled nitric oxide identifies the persistent eosinophilic phenotype in severe refractory asthma. J Allergy Clin Immunol (2005) 1.16
Genome-wide association study identifies TH1 pathway genes associated with lung function in asthmatic patients. J Allergy Clin Immunol (2013) 1.15
Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol (2012) 1.14
Narrative review: the role of Th2 immune pathway modulation in the treatment of severe asthma and its phenotypes. Ann Intern Med (2010) 1.13
Asthma diagnosis and airway bronchodilator response in HIV-infected patients. J Allergy Clin Immunol (2011) 1.13
Cell-specific activation profile of extracellular signal-regulated kinase 1/2, Jun N-terminal kinase, and p38 mitogen-activated protein kinases in asthmatic airways. J Allergy Clin Immunol (2008) 1.11
Genome-wide association studies of asthma indicate opposite immunopathogenesis direction from autoimmune diseases. J Allergy Clin Immunol (2012) 1.11
Regional fibroblast heterogeneity in the lung: implications for remodeling. Am J Respir Crit Care Med (2006) 1.10
Gender differences in IgE-mediated allergic asthma in the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study. J Asthma (2006) 1.10
IL-4 receptor α polymorphisms are predictors of a pharmacogenetic response to a novel IL-4/IL-13 antagonist. J Allergy Clin Immunol (2010) 1.06
Interleukin-13-induced MUC5AC is regulated by 15-lipoxygenase 1 pathway in human bronchial epithelial cells. Am J Respir Crit Care Med (2009) 1.05
The role of cytokines in chronic rhinosinusitis with nasal polyps. Curr Opin Otolaryngol Head Neck Surg (2008) 1.04
Prostaglandin D₂ pathway upregulation: relation to asthma severity, control, and TH2 inflammation. J Allergy Clin Immunol (2013) 1.04
IgE expression pattern in lung: relation to systemic IgE and asthma phenotypes. J Allergy Clin Immunol (2007) 1.01
Assessment of asthma control and asthma exacerbations in the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) observational cohort. Curr Respir Care Rep (2012) 1.01
The IL6R variation Asp(358)Ala is a potential modifier of lung function in subjects with asthma. J Allergy Clin Immunol (2012) 0.98
Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbation. J Allergy Clin Immunol (2010) 0.97
IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor α antagonist. J Allergy Clin Immunol (2012) 0.96
Safety of investigative bronchoscopy in the Severe Asthma Research Program. J Allergy Clin Immunol (2011) 0.95
Genome-wide ancestry association testing identifies a common European variant on 6q14.1 as a risk factor for asthma in African American subjects. J Allergy Clin Immunol (2012) 0.95
Sleep quality and asthma control and quality of life in non-severe and severe asthma. Sleep Breath (2011) 0.94
Interleukin-13 augments transforming growth factor-beta1-induced tissue inhibitor of metalloproteinase-1 expression in primary human airway fibroblasts. Am J Physiol Cell Physiol (2004) 0.93
Genomic differences distinguish the myofibroblast phenotype of distal lung fibroblasts from airway fibroblasts. Am J Respir Cell Mol Biol (2011) 0.93
Allergen-dependent solubilization of IL-13 receptor alpha2 reveals a novel mechanism to regulate allergy. J Allergy Clin Immunol (2006) 0.91
Pathobiology of severe asthma. Annu Rev Pathol (2014) 0.91
Phenotypes in asthma: useful guides for therapy, distinct biological processes, or both? Am J Respir Crit Care Med (2004) 0.91
Current concepts of severe asthma. J Clin Invest (2016) 0.91
Characteristics of perimenstrual asthma and its relation to asthma severity and control: data from the Severe Asthma Research Program. Chest (2013) 0.89
Subtle immunodeficiency in severe asthma: IgA and IgG2 correlate with lung function and symptoms. Int Arch Allergy Immunol (2006) 0.88
Dupilumab in persistent asthma. N Engl J Med (2013) 0.88
Human neutrophil elastase degrades SPLUNC1 and impairs airway epithelial defense against bacteria. PLoS One (2013) 0.88
Establishment of extracellular signal-regulated kinase 1/2 bistability and sustained activation through Sprouty 2 and its relevance for epithelial function. Mol Cell Biol (2010) 0.88
Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients. J Allergy Clin Immunol (2012) 0.87
Protective effects of tanshinone IIA on myocardial ischemia reperfusion injury by reducing oxidative stress, HMGB1 expression, and inflammatory reaction. Pharm Biol (2015) 0.87
Enhanced suppressive function of regulatory T cells from patients with immune-mediated diseases following successful ex vivo expansion. Clin Immunol (2010) 0.85
Mechanisms of tissue inhibitor of metalloproteinase 1 augmentation by IL-13 on TGF-beta 1-stimulated primary human fibroblasts. J Allergy Clin Immunol (2007) 0.85